Immix Biopharma Inc Cash Flow Conversion Efficiency
Immix Biopharma Inc cash flow conversion efficiency. Based on the latest financial reports, Immix Biopharma Inc (IMMX) has a cash flow conversion efficiency ratio of -0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.74 Million) by net assets ($228.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immix Biopharma Inc (2019–2025)
Cash flow conversion efficiency of Immix Biopharma Inc from 2019 to 2025. This chart illustrates how Immix Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Immix Biopharma Inc for real-time trading data and today's change.
Immix Biopharma Inc Cash Flow Conversion Ratio Explained
Immix Biopharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immix Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immix Biopharma Inc ranked by their cash flow conversion efficiency. Also see Immix Biopharma Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Xinneng Photovoltaic Technology Co Ltd
SHG:603105
|
0.082x |
|
Nextool Technology Co. Ltd. A
SHG:688419
|
N/A |
|
Groupe CRIT SA
PA:CEN
|
0.112x |
|
Zhejiang Meida Industrial Co Ltd
SHE:002677
|
0.005x |
|
Jinling Pharmaceutical Co Ltd
SHE:000919
|
0.015x |
|
Woori Technology Inc
KQ:032820
|
-0.028x |
|
Northern United Publishing & Media Group Co Ltd
SHG:601999
|
-0.032x |
|
Hebei Sailhero Environmental
SHE:300137
|
0.020x |
Annual Cash Flow Conversion Efficiency for Immix Biopharma Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Immix Biopharma Inc from 2019 to 2025. Review Immix Biopharma Inc (IMMX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $93.80 Million | $-23.93 Million | -0.255x | +76.84% |
| 2024-12-31 | $13.25 Million | $-14.60 Million | -1.101x | -56.94% |
| 2023-12-31 | $16.20 Million | $-11.37 Million | -0.702x | -24.66% |
| 2022-12-31 | $13.16 Million | $-7.41 Million | -0.563x | -537.23% |
| 2021-12-31 | $17.99 Million | $-1.59 Million | -0.088x | -203.27% |
| 2020-12-31 | $-4.73 Million | $-404.69K | 0.086x | -60.52% |
| 2019-12-31 | $-3.65 Million | $-790.03K | 0.217x | -- |
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.